Name of journal: World Journal of Clinical Cases

Manuscript NO: 77447

Title: The role of visfatin in obesity-induced insulin resistance

Provenance and peer review: Invited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer’s code: 03831562

Position: Peer Reviewer

Academic degree: MD

Professional title: Doctor

Reviewer’s Country/Territory: India

Author’s Country/Territory: Malaysia

Manuscript submission date: 2022-04-30

Reviewer chosen by: AI Technique

Reviewer accepted review: 2022-05-01 04:30

Reviewer performed review: 2022-05-01 05:26

Review time: 1 Hour

<table>
<thead>
<tr>
<th>Scientific quality</th>
<th>[ ] Grade A: Excellent</th>
<th>[ ] Grade B: Very good</th>
<th>[ ] Grade C: Good</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>[ ] Grade D: Fair</td>
<td>[ ] Grade E: Do not publish</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Language quality</th>
<th>[ ] Grade A: Priority publishing</th>
<th>[ ] Grade B: Minor language polishing</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>[ ] Grade C: A great deal of language polishing</td>
<td>[ ] Grade D: Rejection</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Conclusion</th>
<th>[ ] Accept (High priority)</th>
<th>[ ] Accept (General priority)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>[ ] Minor revision</td>
<td>[ ] Major revision</td>
</tr>
</tbody>
</table>

| Re-review           | [ ] Yes                   | [ ] No                       |

| Peer-reviewer       | Peer-Review: [ ] Anonymous | [ ] Onymous |

SPECIFIC COMMENTS TO AUTHORS

COMMENTS TO THE AUTHORS
1. On the whole, a nicely compiled review.
2. The author may please dwell on HOMA-IR and other indices of insulin resistance, including the surrogate Triacylglycerol/High Density Lipoprotein ratio (TAG/HDL).
3. Visfatin is relatively new. The author would do well in adding a paragraph on established adipokines and their gene polymorphism on insulin resistance e.g. Adiponectin SNP+45 and how visceral fat as an adipocyte hormone is unique with reference to adipokines released from adipose tissues.
**Name of journal:** World Journal of Clinical Cases

**Manuscript NO:** 77447

**Title:** The role of visfatin in obesity-induced insulin resistance

**Provenance and peer review:** Invited Manuscript; Externally peer reviewed

**Peer-review model:** Single blind

**Reviewer’s code:** 04152279

**Position:** Peer Reviewer

**Academic degree:** MD

**Professional title:** Doctor

**Reviewer’s Country/Territory:** China

**Author’s Country/Territory:** Malaysia

**Manuscript submission date:** 2022-04-30

**Reviewer chosen by:** AI Technique

**Reviewer accepted review:** 2022-05-01 05:12

**Reviewer performed review:** 2022-05-04 02:04

**Review time:** 2 Days and 20 Hours

<table>
<thead>
<tr>
<th>Scientific quality</th>
<th>[ ] Grade A: Excellent</th>
<th>[ ] Grade B: Very good</th>
<th>[ ] Grade C: Good</th>
<th>[ ] Grade D: Fair</th>
<th>[ ] Grade E: Do not publish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Language quality</td>
<td>[ ] Grade A: Priority publishing</td>
<td>[ ] Grade B: Minor language polishing</td>
<td>[ ] Grade C: A great deal of language polishing</td>
<td>[ ] Grade D: Rejection</td>
<td></td>
</tr>
<tr>
<td>Conclusion</td>
<td>[ ] Accept (High priority)</td>
<td>[ ] Accept (General priority)</td>
<td>[ ] Minor revision</td>
<td>[ ] Major revision</td>
<td>[ ] Rejection</td>
</tr>
<tr>
<td>Re-review</td>
<td>[ ] Yes</td>
<td>[ ] No</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Peer-reviewer</td>
<td>Peer-Review: [ ] Anonymous</td>
<td>[ ] Onymous</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
SPECIFIC COMMENTS TO AUTHORS
1. If the parts about visfatin level and cardiovascular diseases and kidney diseases in the text can be properly reflected in the abstract, it can make the abstract more comprehensive; 2. If the keywords can be added "PBEF" and "Nampt", it can make the article easier to be searched; 3. In figure 1 "nicotinamide phosphoribosyltransferase" is different with the "nicotinamide phosphoribosyltransferase" in article, whether there is a writing error; 4. "Dexamethasone" and "Somatostatin" in Figure 2 are inconsistent with the description in the paper, please modify them to make the paper more rigorous; 5. If you can improve the expression and make the article more logical, your writing will be much clearer and easier to understand. 6. Please mark the preface in your article to make the structure of the article clearer.
Name of journal: World Journal of Clinical Cases
Manuscript NO: 77447
Title: The role of visfatin in obesity-induced insulin resistance

Provenance and peer review: Invited Manuscript; Externally peer reviewed

Peer-review model: Single blind
Reviewer’s code: 02455955
Position: Associate Editor
Academic degree: BMed, PhD
Professional title: Dean, Professor
Reviewer’s Country/Territory: China
Author’s Country/Territory: Malaysia
Manuscript submission date: 2022-04-30
Reviewer chosen by: AI Technique
Reviewer accepted review: 2022-05-01 03:29
Reviewer performed review: 2022-05-05 02:50
Review time: 3 Days and 23 Hours

Scientific quality
[ ] Grade A: Excellent
[ ] Grade B: Very good
[Y] Grade C: Good
[ ] Grade D: Fair
[ ] Grade E: Do not publish

Language quality
[ ] Grade A: Priority publishing
[ ] Grade B: Minor language polishing
[Y] Grade C: A great deal of language polishing
[ ] Grade D: Rejection

Conclusion
[ ] Accept (High priority)
[ ] Accept (General priority)
[Y] Minor revision
[ ] Major revision
[ ] Rejection

Re-review
[Y] Yes
[ ] No

Peer-reviewer
Peer-Review: [Y] Anonymous
[ ] Onymous
SPECIFIC COMMENTS TO AUTHORS

General comments: This study reviews the relationship between visfatin level and insulin resistance in obesity, cardiovascular disease, and kidney disease. The authors discuss the role of lipids in the development of IR by referring to a large number of existing literature, and discuss in detail the potential use of salivary visfatin level as biomarkers for early detection of IR and IR-related diseases. This topic is novel and has potential clinical diagnostic value, but there are some problems which need to be discussed in more detail. Specific comments: 1. In INTRODUCTION, this sentence “to the absence of correlation between plasma visfatin level and diabetes” was taken out of context. This is an uncertain conclusion due to the small sample size of the cited article. Studies have shown that plasma visfatin concentration has been reported to be significantly associated with T2DM and with lower glucose concentrations, and visfatin inhibits hepatic glucose production by stimulating glucose transport in adipocytes and muscle. 2. TNF-a is also a common cause of insulin resistance. Studies have shown that there is a significant correlation between plasma visfatin level, TNF-a and insulin resistance. Please add relevant content in this review. 3. The adipocytokines secreted from the adipose tissue, increased white blood cell count and exosome have been studied as biomarkers for insulin resistance. Exosomes are present in a variety of body fluids, such as plasma, saliva, breast milk, sweat, tears and urine, and are a promising method for the early diagnosis of insulin resistance. Please describe the advantages and prospects of using serum or salivary visfatin levels as biomarkers of insulin resistance.